1
|
Kim MC, De U, Borcherding N, Wang L, Paek J, Bhattacharyya I, Yu Q, Kolb R, Drashansky T, Thatayatikom A, Zhang W, Cha S. Single-cell transcriptomics unveil profiles and interplay of immune subsets in rare autoimmune childhood Sjögren's disease. Commun Biol 2024; 7:481. [PMID: 38641668 PMCID: PMC11031574 DOI: 10.1038/s42003-024-06124-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Accepted: 03/29/2024] [Indexed: 04/21/2024] Open
Abstract
Childhood Sjögren's disease represents critically unmet medical needs due to a complete lack of immunological and molecular characterizations. This study presents key immune cell subsets and their interactions in the periphery in childhood Sjögren's disease. Here we show that single-cell RNA sequencing identifies the subsets of IFN gene-enriched monocytes, CD4+ T effector memory, and XCL1+ NK cells as potential key players in childhood Sjögren's disease, and especially in those with recurrent parotitis, which is the chief symptom prompting clinical visits from young children. A unique cluster of monocytes with type I and II IFN-related genes is identified in childhood Sjögren's disease, compared to the age-matched control. In vitro regulatory T cell functional assay demonstrates intact functionality in childhood Sjögren's disease in contrast to reduced suppression in adult Sjögren's disease. Mapping this transcriptomic landscape and interplay of immune cell subsets will expedite the understanding of childhood Sjögren's disease pathogenesis and set the foundation for precision medicine.
Collapse
Affiliation(s)
- Myung-Chul Kim
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
- Diagnostic Laboratory Medicine, College of Veterinary Medicine, Jeju National University, Jeju, 63243, Republic of Korea
- Research Institute of Veterinary Medicine, College of Veterinary Medicine, Jeju National University, Jeju, 63243, Republic of Korea
- Center for Orphaned Autoimmune Disorders, University of Florida College of Dentistry, Gainesville, FL, 32610, USA
| | - Umasankar De
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
| | - Nicholas Borcherding
- Department of Pathology & Immunology, Washington University School of Medicine in St. Louis, St Louis, MO, 63110, USA
| | - Lei Wang
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
| | - Joon Paek
- Center for Orphaned Autoimmune Disorders, University of Florida College of Dentistry, Gainesville, FL, 32610, USA
- Department of Pathology & Immunology, Washington University School of Medicine in St. Louis, St Louis, MO, 63110, USA
| | - Indraneel Bhattacharyya
- Center for Orphaned Autoimmune Disorders, University of Florida College of Dentistry, Gainesville, FL, 32610, USA
- Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, 32610, USA
| | - Qing Yu
- The Forsyth Institute, Cambridge, MA, 02142, USA
| | - Ryan Kolb
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
| | | | | | - Weizhou Zhang
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, 32610, USA.
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA.
| | - Seunghee Cha
- Center for Orphaned Autoimmune Disorders, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
- Department of Oral & Maxillofacial Diagnostic Sciences, University of Florida College of Dentistry, Gainesville, FL, 32610, USA.
| |
Collapse
|
2
|
Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC, Liu Y, Maharjan CK, Patel UM, De U, Carelock ME, Tithi TI, Li X, Shaffer DR, Guertin KR, Zhuang H, Moser E, Smalley KS, Lv D, Zhou D, Zheng G, Zhang W. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med 2024; 221:e20231519. [PMID: 38334978 PMCID: PMC10857906 DOI: 10.1084/jem.20231519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 12/01/2023] [Accepted: 01/22/2024] [Indexed: 02/10/2024] Open
Abstract
An effective cancer therapy requires killing cancer cells and targeting the tumor microenvironment (TME). Searching for molecules critical for multiple cell types in the TME, we identified NR4A1 as one such molecule that can maintain the immune suppressive TME. Here, we establish NR4A1 as a valid target for cancer immunotherapy and describe a first-of-its-kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 degrades NR4A1 within hours in vitro and exhibits long-lasting NR4A1 degradation in tumors with an excellent safety profile. NR-V04 inhibits and frequently eradicates established tumors. At the mechanistic level, NR-V04 induces the tumor-infiltrating (TI) B cells and effector memory CD8+ T (Tem) cells and reduces monocytic myeloid-derived suppressor cells (m-MDSC), all of which are known to be clinically relevant immune cell populations in human melanomas. Overall, NR-V04-mediated NR4A1 degradation holds promise for enhancing anticancer immune responses and offers a new avenue for treating various types of cancers such as melanoma.
Collapse
Affiliation(s)
- Lei Wang
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Yufeng Xiao
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Yuewan Luo
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Rohan P. Master
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Jiao Mo
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Myung-Chul Kim
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
- Veterinary Diagnostic Laboratory Medicine, College of Veterinary Medicine, Jeju National University, Jeju-si, South Korea
| | - Yi Liu
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Chandra K. Maharjan
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Urvi M. Patel
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Umasankar De
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Madison E. Carelock
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Tanzia Islam Tithi
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | | | | | | | - Haoyang Zhuang
- Rheumatology and Clinical Immunology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Emily Moser
- Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Keiran S.M. Smalley
- Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - Dongwen Lv
- Department of Biochemistry and Structural Biology, Center of Innovative Drug Discovery, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Daohong Zhou
- Department of Biochemistry and Structural Biology, Center of Innovative Drug Discovery, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
| | - Guangrong Zheng
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
- University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA
| | - Weizhou Zhang
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
- University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA
| |
Collapse
|
3
|
Dupéré-Richer D, Riva A, Maji S, Barwick BG, Román HC, Sobh A, Quickstad G, Li J, De U, Piper C, Kulis M, Ezponda T, Martin-Subero JI, Tonon G, Zhang W, Mitsiades CS, Boise LH, Bennett RL, Licht JD. KDM6A Regulates Immune Response Genes in Multiple Myeloma. bioRxiv 2024:2024.02.12.579179. [PMID: 38405853 PMCID: PMC10888870 DOI: 10.1101/2024.02.12.579179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/27/2024]
Abstract
The histone H3K27 demethylase KDM6A is a tumor suppressor in multiple cancers, including multiple myeloma (MM). We created isogenic MM cells disrupted for KDM6A and tagged the endogenous protein to facilitate genome wide studies. KDM6A binds genes associated with immune recognition and cytokine signaling. Most importantly, KDM6A binds and activates NLRC5 and CIITA encoding regulators of Major Histocompatibility Complex (MHC) genes. Patient data indicate that NLRC5 and CIITA, are downregulated in MM with low KDM6A expression. Chromatin analysis shows that KDM6A binds poised and active enhancers and KDM6A loss led to decreased H3K27ac at enhancers, increased H3K27me3 levels in body of genes bound by KDM6A and decreased gene expression. Reestablishing histone acetylation with an HDAC3 inhibitor leads to upregulation of MHC expression, offering a strategy to restore immunogenicity of KDM6A deficient tumors. Loss of Kdm6a in murine RAS-transformed fibroblasts led to increased growth in vivo associated with decreased T cell infiltration. Statement of significance We show that KDM6A participates in immune recognition of myeloma tumor cells by directly regulating the expression of the master regulators of MHC-I and II, NLRC5 and CIITA. The expression of these regulators can by rescued by the HDAC3 inhibitors in KDM6A-null cell lines.
Collapse
|
4
|
Jin Z, De U, Wang L, Kleberg J, Zhang W, Kolb R. Abstract 571: Angiopoietin-like 4 as a potential therapeutic target for clear cell renal carcinoma. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
Renal cell carcinoma (RCC) is the 7th most common type of cancer, with over 400,000 new cases each year and 170,000 deaths worldwide. RCCs are grouped into several histological subtypes, with clear cell renal cell carcinoma (ccRCC) being the most common and most aggressive type. The first line of therapy for ccRCC is tyrosine kinase inhibitors (TKIs) which target multiple kinases including the VEGF receptor. The treatment can be used alone or in combination with immune checkpoint inhibitors. However, most patients develop resistance to the TKIs within six months of treatment. Therefore, our aim is to develop novel single or combinatorial therapies and discover ways to overcome the resistance to TKIs. By analyzing TCGA and published datasets from GEO, we found that angiopoietin-like 4 (ANGPTL4) is significantly elevated in both the WT and TKI-resistant ccRCC tumors. ANGPTL4 has been shown to participate in angiogenesis in several other tumor models, and blocking ANGPTL4 with an antibody in vitro, reduces the angiogenic potential of 786-O and RCC4 human ccRCC cell lines, suggesting a pro-angiogenic effect of ANGPTL4 in ccRCC. Knockout of ANGPTL4 in Caki-1 xenograft tumor model significantly reduced tumor angiogenesis and increased vessel normalization, as evidenced by increased expression of VEGFR2 and adhesion molecules on endothelial cells. The increased normalization of blood vessels is an indication of the therapeutic potential of combing anti-ANGPTL4 therapy with immune checkpoint inhibitors. Furthermore, both knockout of ANGPTL4 in 786-O cells and treatment of 786-O tumor-bearing mice with an ANGPTL4 blocking antibody significantly reduced tumor growth. To illustrate the mechanism of ANGPTL4-induced angiogenesis, we performed live cell receptor capturing to find cANGPTL4 binding partners on the cell membrane of human endothelial cells. After the mass spectrometry analysis, several novel receptors were found, and the top candidate is endothelial cell surface chemotaxis receptor (ECSCR), which is highly expressed on endothelial and adipocytes. Previous studies have shown that ECSCR can potentiate angiogenic signaling, which is similar to our data showing that ANGPTL4 can synergistically increase FGF2-induced angiogenesis. Thus, ANGPTL4 may promote angiogenesis in ccRCC by potentiating other angiogenic signaling via interaction with ECSCR. To summarize, we demonstrated the pro-angiogenic potential of ANGPTL4 in ccRCC and its critical role in tumor development. Knockout or antibody-mediated inhibition of ANGPTL4 reduced tumor angiogenesis and growth and increased vessel normalization. This data supports the therapeutic potential of ANGPTL4 targeted treatment in ccRCC.
Citation Format: Zeng Jin, Umasankar De, Lei Wang, Jeremy Kleberg, Weizhou Zhang, Ryan Kolb. Angiopoietin-like 4 as a potential therapeutic target for clear cell renal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 571.
Collapse
Affiliation(s)
- Zeng Jin
- 1University of Florida College of Medicine, Gainesville, FL
| | - Umasankar De
- 1University of Florida College of Medicine, Gainesville, FL
| | - Lei Wang
- 1University of Florida College of Medicine, Gainesville, FL
| | - Jeremy Kleberg
- 1University of Florida College of Medicine, Gainesville, FL
| | - Weizhou Zhang
- 1University of Florida College of Medicine, Gainesville, FL
| | - Ryan Kolb
- 1University of Florida College of Medicine, Gainesville, FL
| |
Collapse
|
5
|
Khan S, Kellish P, Connis N, Thummuri D, Wiegand J, Zhang P, Zhang X, Budamagunta V, Hua N, Yang Y, De U, Jin L, Zhang W, Zheng G, Hromas R, Hann C, Zajac-Kaye M, Kaye FJ, Zhou D. Co-targeting BCL-X L and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice. Cell Death Dis 2023; 9:1. [PMID: 36588105 PMCID: PMC9806104 DOI: 10.1038/s41420-022-01296-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2022] [Revised: 12/20/2022] [Accepted: 12/22/2022] [Indexed: 01/03/2023]
Abstract
Small-cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. The dismal prognosis in SCLC is in part associated with an upregulation of BCL-2 family anti-apoptotic proteins, including BCL-XL and MCL-1. Unfortunately, the currently available inhibitors of BCL-2 family anti-apoptotic proteins, except BCL-2 inhibitors, are not clinically relevant because of various on-target toxicities. We, therefore, aimed to develop an effective and safe strategy targeting these anti-apoptotic proteins with DT2216 (our platelet-sparing BCL-XL degrader) and AZD8055 (an mTOR inhibitor) to avoid associated on-target toxicities while synergistically optimizing tumor response. Through BH3 mimetic screening, we identified a subset of SCLC cell lines that is co-dependent on BCL-XL and MCL-1. After screening inhibitors of selected tumorigenic pathways, we found that AZD8055 selectively downregulates MCL-1 in SCLC cells and its combination with DT2216 synergistically killed BCL-XL/MCL-1 co-dependent SCLC cells, but not normal cells. Mechanistically, the combination caused BCL-XL degradation and suppression of MCL-1 expression, and thus disrupted MCL-1 interaction with BIM leading to an enhanced apoptotic induction. In vivo, the DT2216 + AZD8055 combination significantly inhibited the growth of cell line-derived and patient-derived xenografts and reduced tumor burden accompanied by increased survival in a genetically engineered mouse model of SCLC without causing appreciable thrombocytopenia or other normal tissue injuries. Thus, these preclinical findings lay a strong foundation for future clinical studies to test DT2216 + mTOR inhibitor combinations in a subset of SCLC patients whose tumors are co-driven by BCL-XL and MCL-1.
Collapse
Affiliation(s)
- Sajid Khan
- Department of Biochemistry & Structural Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. .,Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. .,Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
| | - Patrick Kellish
- grid.15276.370000 0004 1936 8091Department of Anatomy & Cell Biology, College of Medicine, University of Florida, Gainesville, FL USA ,grid.15276.370000 0004 1936 8091Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Nick Connis
- grid.21107.350000 0001 2171 9311Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD USA
| | - Dinesh Thummuri
- grid.15276.370000 0004 1936 8091Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Janet Wiegand
- grid.15276.370000 0004 1936 8091Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Peiyi Zhang
- grid.15276.370000 0004 1936 8091Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Xuan Zhang
- grid.15276.370000 0004 1936 8091Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Vivekananda Budamagunta
- grid.15276.370000 0004 1936 8091Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA ,grid.15276.370000 0004 1936 8091Genetics and Genomics Graduate Program, Genetics Institute, College of Medicine, University of Florida, Gainesville, FL USA ,grid.15276.370000 0004 1936 8091Department of Neuroscience, College of Medicine, University of Florida, Gainesville, FL USA
| | - Nan Hua
- grid.15276.370000 0004 1936 8091Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Yang Yang
- grid.267309.90000 0001 0629 5880Department of Biochemistry & Structural Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA ,grid.15276.370000 0004 1936 8091Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Umasankar De
- grid.15276.370000 0004 1936 8091Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL USA
| | - Lingtao Jin
- grid.267309.90000 0001 0629 5880Department of Molecular Medicine, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA
| | - Weizhou Zhang
- grid.15276.370000 0004 1936 8091Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL USA
| | - Guangrong Zheng
- grid.15276.370000 0004 1936 8091Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL USA
| | - Robert Hromas
- grid.267309.90000 0001 0629 5880Department of Medicine, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA
| | - Christine Hann
- grid.21107.350000 0001 2171 9311Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD USA
| | - Maria Zajac-Kaye
- grid.15276.370000 0004 1936 8091Department of Anatomy & Cell Biology, College of Medicine, University of Florida, Gainesville, FL USA
| | - Frederic J. Kaye
- grid.15276.370000 0004 1936 8091Division of Hematology and Oncology, Department of Medicine, College of Medicine, University of Florida, Gainesville, FL USA
| | - Daohong Zhou
- grid.267309.90000 0001 0629 5880Department of Biochemistry & Structural Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX USA ,grid.267309.90000 0001 0629 5880Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX USA ,grid.15276.370000 0004 1936 8091Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL USA
| |
Collapse
|
6
|
Kim MC, Borcherding N, Ahmed KK, Voigt AP, Vishwakarma A, Kolb R, Kluz PN, Pandey G, De U, Drashansky T, Helm EY, Zhang X, Gibson-Corley KN, Klesney-Tait J, Zhu Y, Lu J, Lu J, Huang X, Xiang H, Cheng J, Wang D, Wang Z, Tang J, Hu J, Wang Z, Liu H, Li M, Zhuang H, Avram D, Zhou D, Bacher R, Zheng SG, Wu X, Zakharia Y, Zhang W. CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nat Commun 2021; 12:5764. [PMID: 34599187 PMCID: PMC8486774 DOI: 10.1038/s41467-021-26091-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Accepted: 09/17/2021] [Indexed: 12/23/2022] Open
Abstract
Regulatory T (Treg) cells are one of the major immunosuppressive cell types in cancer and a potential target for immunotherapy, but targeting tumor-infiltrating (TI) Treg cells has been challenging. Here, using single-cell RNA sequencing of immune cells from renal clear cell carcinoma (ccRCC) patients, we identify two distinct transcriptional fates for TI Treg cells, Fate-1 and Fate-2. The Fate-1 signature is associated with a poorer prognosis in ccRCC and several other solid cancers. CD177, a cell surface protein normally expressed on neutrophil, is specifically expressed on Fate-1 TI Treg cells in several solid cancer types, but not on other TI or peripheral Treg cells. Mechanistically, blocking CD177 reduces the suppressive activity of Treg cells in vitro, while Treg-specific deletion of Cd177 leads to decreased tumor growth and reduced TI Treg frequency in mice. Our results thus uncover a functional CD177+ TI Treg population that may serve as a target for TI Treg-specific immunotherapy.
Collapse
MESH Headings
- Animals
- Base Sequence
- Carcinogenesis/genetics
- Carcinogenesis/pathology
- Carcinoma, Renal Cell/genetics
- Carcinoma, Renal Cell/immunology
- Carcinoma, Renal Cell/pathology
- GPI-Linked Proteins/deficiency
- GPI-Linked Proteins/metabolism
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Homeostasis
- Humans
- Isoantigens/metabolism
- Kidney Neoplasms/genetics
- Kidney Neoplasms/immunology
- Kidney Neoplasms/pathology
- Lymphocytes, Tumor-Infiltrating/metabolism
- Mice, Knockout
- Prognosis
- Receptors, Cell Surface/deficiency
- Receptors, Cell Surface/metabolism
- Single-Cell Analysis
- T-Lymphocytes, Regulatory/metabolism
- Transcription, Genetic
- Mice
Collapse
Affiliation(s)
- Myung-Chul Kim
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
| | - Nicholas Borcherding
- Department of Pathology, University of Iowa, Iowa City, IA, 52242, USA
- Cancer Biology Graduate Program, University of Iowa, Iowa City, IA, 52242, USA
- Medical Scientist Training Program, University of Iowa, Iowa City, IA, 52242, USA
| | - Kawther K Ahmed
- Department of Pathology, University of Iowa, Iowa City, IA, 52242, USA
- College of Pharmacy, University of Baghdad, Department of Pharmaceutics, Baghdad, 10071, Iraq
| | - Andrew P Voigt
- Medical Scientist Training Program, University of Iowa, Iowa City, IA, 52242, USA
| | - Ajaykumar Vishwakarma
- Cancer Biology Graduate Program, University of Iowa, Iowa City, IA, 52242, USA
- Department of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, IA52242, USA
| | - Ryan Kolb
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
| | - Paige N Kluz
- Department of Pathology, University of Iowa, Iowa City, IA, 52242, USA
| | - Gaurav Pandey
- Department of Pathology, University of Iowa, Iowa City, IA, 52242, USA
- Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, 63110, USA
| | - Umasankar De
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, 32610, USA
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
| | - Theodore Drashansky
- Department of Anatomy and Cell Biology, University of Florida College of Medicine, 32610, Gainesville, FL, 32610, USA
| | - Eric Y Helm
- Department of Anatomy and Cell Biology, University of Florida College of Medicine, 32610, Gainesville, FL, 32610, USA
| | - Xin Zhang
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
- Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Fl, 32610, USA
| | - Katherine N Gibson-Corley
- Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232-2130, USA
| | - Julia Klesney-Tait
- Department of Internal Medicine, University of Iowa, Iowa City, IA, 52242, USA
| | - Yuwen Zhu
- Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA
| | - Jinglu Lu
- Department of Breast Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China
| | - Jinsong Lu
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Xian Huang
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Hongrui Xiang
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Jinke Cheng
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Dongyang Wang
- Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China
| | - Zheng Wang
- Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China
| | - Jian Tang
- Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China
| | - Jiajia Hu
- Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Zhengting Wang
- Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Hua Liu
- Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Mingjia Li
- Department of Medicine, Division of Rheumatology & Clinical Immunology, University of Florida, 1600 Archer Road, Gainesville, FL, 32610-0275, USA
| | - Haoyang Zhuang
- Department of Medicine, Division of Rheumatology & Clinical Immunology, University of Florida, 1600 Archer Road, Gainesville, FL, 32610-0275, USA
| | - Dorina Avram
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
- Department of Anatomy and Cell Biology, University of Florida College of Medicine, 32610, Gainesville, FL, 32610, USA
- Department of Immunology, Moffitt Cancer Center, Tampa, FL, 33612, USA
| | - Daohong Zhou
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA
- Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Fl, 32610, USA
| | - Rhonda Bacher
- Department of Biostatistics, University of Florida, Gainesville, FL, 32610, USA
| | - Song Guo Zheng
- Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, 43210, USA
| | - Xuefeng Wu
- Department of Breast Surgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, 200127, China.
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
- Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
| | - Yousef Zakharia
- Department of Pathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, TN, 37232-2130, USA.
| | - Weizhou Zhang
- Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, FL, 32610, USA.
- UF Health Cancer Center, University of Florida, Gainesville, FL, 32610, USA.
- Department of Pathology, University of Iowa, Iowa City, IA, 52242, USA.
| |
Collapse
|
7
|
Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-X L destroys tumor-infiltrating regulatory T cells. Nat Commun 2021; 12:1281. [PMID: 33627663 PMCID: PMC7904819 DOI: 10.1038/s41467-021-21573-x] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Accepted: 02/01/2021] [Indexed: 12/13/2022] Open
Abstract
Regulatory T cells (Tregs) play an important role in maintaining immune homeostasis and, within tumors, their upregulation is common and promotes an immunosuppressive microenvironment. Therapeutic strategies that can eliminate Tregs in the tumor (i.e., therapies that do not run the risk of affecting normal tissues), are urgently needed for the development of cancer immunotherapies. Here we report our discovery of B-cell lymphoma extra-large (BCL-XL) as a potential molecular target of tumor-infiltrating (TI) Tregs. We show that pharmacological degradation of BCL-XL using a newly developed platelet-sparing BCL-XL Proteolysis-targeting chimera (PROTAC) induces the apoptosis of TI-Tregs and the activation of TI-CD8+ T cells. Moreover, these activities result in an effective suppression of syngeneic tumor growth in immunocompetent, but not in immunodeficient or CD8+ T cell-depleted mice. Notably, treatment with BCL-XL PROTAC does not cause detectable damage within several normal tissues or thrombocytopenia. These findings identify BCL-XL as a target in the elimination of TI-Tregs as a component of cancer immunotherapies, and that the BCL-XL-specific PROTAC has the potential to be developed as a therapeutic for cancer immunotherapy. Targeting regulatory T cells (Treg) represents a therapeutic option to abrogate tumor-associated immune suppression. Here the authors show that pharmacological degradation of BCL-XL preferentially induces apoptosis of tumor-infiltrating Treg, promoting CD8 T cell activation and anti-tumor immune responses in preclinical cancer models.
Collapse
Affiliation(s)
- Ryan Kolb
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.,University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA
| | - Umasankar De
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Sajid Khan
- Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Yuewan Luo
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Myung-Chul Kim
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Haijun Yu
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Chaoyan Wu
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Jiao Mo
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
| | - Xin Zhang
- Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Peiyi Zhang
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Xuan Zhang
- Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | | | - Daniel Koppel
- University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.,Department of Chemistry, College of Liberal Art and Sciences, University of Florida, Gainesville, FL, USA
| | - Yang-Xin Fu
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA
| | - Song Guo Zheng
- Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH, USA
| | - Dorina Avram
- University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.,Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL, USA.,Department of Immunology, Moffitt Cancer Center, Tampa, FL, USA
| | - Guangrong Zheng
- University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.,Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA
| | - Daohong Zhou
- University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA. .,Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, FL, USA.
| | - Weizhou Zhang
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA. .,University of Florida Health Cancer Center, University of Florida, Gainesville, FL, USA.
| |
Collapse
|
8
|
De U, Son JY, Jeon Y, Ha SY, Park YJ, Yoon S, Ha KT, Choi WS, Lee BM, Kim IS, Kwak JH, Kim HS. Plumbagin from a tropical pitcher plant (Nepenthes alata Blanco) induces apoptotic cell death via a p53-dependent pathway in MCF-7 human breast cancer cells. Food Chem Toxicol 2018; 123:492-500. [PMID: 30458268 DOI: 10.1016/j.fct.2018.11.040] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Revised: 11/14/2018] [Accepted: 11/16/2018] [Indexed: 12/16/2022]
Abstract
Plumbagin (5-hydroxy-2-methyl-1,4-naphthaquinone) has displayed antitumor activity in vitro and in animal models; however, the underlying molecular mechanisms have not been fully explored. The aim of this study was to investigate the anticancer effects of plumbagin isolated from Nepenthes alata against MCF-7 breast cancer cells. We examined the cytotoxicity, cell cycle regulation, apoptotic cell death, and generation of intracellular reactive oxygen species (ROS) in MCF-7 cells. Plumbagin exhibited potent cytotoxicity in MCF-7 cells (wild-type p53) compared to that in SK-OV-3 (null-type) human epithelial ovarian cancer cells. Specifically, plumbagin upregulated the expression of p21CIP1/WAF1 in MCF-7 cells, causing cell cycle arrest in the G2/M phase through inhibition of cyclin B1 levels. Plumbagin also significantly increased the ratio of Bax/Bcl-2 and release of cytochrome c, resulting in apoptotic cell death in MCF-7 cells. Furthermore, plumbagin dramatically increased the intracellular ROS level, whereas pretreatment with the ROS scavenger N-acetyl cysteine protected against plumbagin-induced cytotoxicity, suggesting that ROS formation plays a pivotal role in antitumor activity in MCF-7 cells. In mice bearing MCF-7 cell xenografts, plumbagin significantly reduced tumor growth and weight without apparent side effects. We therefore concluded that plumbagin exerts anticancer activity against MCF-7 cells through the generation of intracellular ROS, resulting in the induction of apoptosis via a p53-dependent pathway. This study thus identifies a new anticancer mechanism of plumbagin against p53-dependent breast cancer cells and suggests a novel strategy for overcoming of breast cancer therapy.
Collapse
Affiliation(s)
- Umasankar De
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Ji Yeon Son
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Yukyoung Jeon
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Song-Yi Ha
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Yu Jin Park
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Sungpil Yoon
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Ki-Tae Ha
- School of Korean Medicine and Healthy Aging Korean Medicine Research Center, Pusan National University, Yangsan, 50612, Republic of Korea
| | - Wahn Soo Choi
- School of Medicine, Konkuk University, Chungju, 27478, Republic of Korea
| | - Byung Mu Lee
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - In Su Kim
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea
| | - Jong Hwan Kwak
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
| |
Collapse
|
9
|
Son JY, Yoon S, Tae IH, Park YJ, De U, Jeon Y, Park YJ, Rhyu IJ, Lee BM, Chung K, Lim JE, Lee SJ, Lee HW, Kwak JH, Kim HS, Choi HY. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways. Cancer Med 2018; 7:5083-5095. [PMID: 30160042 PMCID: PMC6198234 DOI: 10.1002/cam4.1748] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 06/08/2018] [Accepted: 08/05/2018] [Indexed: 12/11/2022] Open
Abstract
Current clinical trials of new anticancer therapies against metastatic renal cell carcinoma (RCC), including molecular-targeted therapies, have not shown promise. The purpose of this study was to preclinically assess the antitumor effects of MC-4, a partially purified material of Artemisia annua L., as a monotherapy or in combination with the known mechanistic target of rapamycin complex 1 (mTORC1) inhibitor, everolimus, against Caki-1 (Von Hippel-Lindau (VHL)+/+) and 786-O (VHL-/-) human RCC cells. MC-4 monotherapy significantly increased tumor growth inhibition and autophagic cell death in RCC cells in vitro and in vivo. Everolimus led to compensatory Akt activation by inhibiting only mTORC1 signaling pathway. In contrast to everolimus, MC-4 enhanced phosphatase and tensin homolog expression and reduced its downstream effector, Akt/pyruvate kinase muscle isozyme M2 (PKM2), leading to decreased expression of glucose transporter 1, which is associated with cancer cell metabolism. The synergistic antitumor and anti-metastatic effects induced by co-administration of MC-4 and everolimus involve cell growth inhibition and autophagic cell death via dual targeting of phosphatidylinositol 3-kinase (PI3K)/Akt/PKM2 and mTORC1. These findings suggest that MC-4 is a novel Akt/PKM2 inhibitor that can overcome the limitation of existing mTOR inhibitors and can be considered a novel strategy to treat patients with rapidly progressing advanced RCC.
Collapse
Affiliation(s)
- Ji Yeon Son
- School of PharmacySungkyunkwan UniversitySuwonKorea
| | - Sungpil Yoon
- School of PharmacySungkyunkwan UniversitySuwonKorea
| | - In Hwan Tae
- School of PharmacySungkyunkwan UniversitySuwonKorea
| | - Yu Jin Park
- School of PharmacySungkyunkwan UniversitySuwonKorea
| | - Umasankar De
- School of PharmacySungkyunkwan UniversitySuwonKorea
| | | | | | - Im Joo Rhyu
- Department of AnatomyKorea University College of MedicineSeoulKorea
| | - Byung Mu Lee
- School of PharmacySungkyunkwan UniversitySuwonKorea
| | | | - Joung Eun Lim
- Departments of UrologySamsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
| | - Se Jeong Lee
- Department of AnatomyKorea University College of MedicineSeoulKorea
| | - Hye Won Lee
- Departments of UrologySamsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea
- Department of Anatomy and Cell BiologySungkyunkwan University School of MedicineSuwonKorea
- Single Cell Network Research CenterSungkyunkwan University School of MedicineSuwonKorea
| | | | | | - Han Yong Choi
- Department of UrologyKangbuk Samsung HospitalSeoulKorea
| |
Collapse
|
10
|
De U, Son JY, Sachan R, Park YJ, Kang D, Yoon K, Lee BM, Kim IS, Moon HR, Kim HS. A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation. Int J Mol Sci 2018; 19:ijms19092743. [PMID: 30217020 PMCID: PMC6164480 DOI: 10.3390/ijms19092743] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2018] [Revised: 09/07/2018] [Accepted: 09/10/2018] [Indexed: 12/28/2022] Open
Abstract
We previously discovered a novel sirtuin (SIRT) inhibitor, MHY2256, that exerts anticancer activity through p53 acetylation in MCF-7 human breast cancer cells. We investigated the anticancer activity of MHY2256 against hormone-related cancer, an endometrial cancer with a poor prognosis. The IC50 values of MHY2256 were shown to be much lower than those of salermide, a well-known SIRT inhibitor. Furthermore, MHY2256 significantly reduced the protein expression and activities of SIRT1, 2, and 3, with similar effects to salermide. Particularly, MHY2256 markedly inhibited tumor growth in a tumor xenograft mouse model of Ishikawa cancer cells. During the experimental period, there was no significant change in the body weight of mice treated with MHY2256. A detailed analysis of the sensitization mechanisms of Ishikawa cells revealed that late apoptosis was largely increased by MHY2256. Additionally, MHY2256 increased G1 arrest and reduced the number of cell cyclic-related proteins, suggesting that apoptosis by MHY2256 was achieved by cellular arrest. Particularly, p21 was greatly increased by MHY225656, suggesting that cell cycle arrest by p21 is a major factor in MHY2256 sensitization in Ishikawa cells. We also detected a significant increase in acetylated p53, a target protein of SIRT1, in Ishikawa cells after MHY2256 treatment. In a mouse xenograft model, MHY2256 significantly reduced tumor growth and weight without apparent side effects. These results suggest that MHY2256 exerts its anticancer activity through p53 acetylation in endometrial cancer and can be used for targeting hormone-related cancers.
Collapse
Affiliation(s)
- Umasankar De
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| | - Ji Yeon Son
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| | - Richa Sachan
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| | - Yu Jin Park
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| | - Dongwan Kang
- College of Pharmacy, Pusan National University, Busandaehak-ro 63 beon-gil 2, Geumjeong-gu, Busan 46241, Korea.
| | - Kyungsil Yoon
- Comparative Biomedicine Research Branch, Division of Translational Science, National Cancer Center, 323 Ilsandong-gu, Goyang-si 10408, Korea.
| | - Byung Mu Lee
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| | - In Su Kim
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| | - Hyung Ryong Moon
- College of Pharmacy, Pusan National University, Busandaehak-ro 63 beon-gil 2, Geumjeong-gu, Busan 46241, Korea.
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 16419, Korea.
| |
Collapse
|
11
|
Roh T, De U, Lim SK, Kim MK, Choi SM, Lim DS, Yoon S, Kacew S, Kim HS, Lee BM. Detoxifying effect of pyridoxine on acetaminophen-induced hepatotoxicity via suppressing oxidative stress injury. Food Chem Toxicol 2018; 114:11-22. [DOI: 10.1016/j.fct.2018.02.017] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 02/01/2018] [Accepted: 02/07/2018] [Indexed: 12/24/2022]
|
12
|
Laha P, De U, Chandra F, Dehury N, Khullar S, Kim HS, Patra S. Alkyl chain-modified cyclometalated iridium complexes as tunable anticancer and imaging agents. Dalton Trans 2018; 47:15873-15881. [DOI: 10.1039/c8dt02461h] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Imidazole-based cyclometalated iridium complexes [1]+–[5]+ have been developed displaying alkyl chain length dependent anticancer activity and imaging property.
Collapse
Affiliation(s)
- Paltan Laha
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Jatni-752050
- India
| | - Umasankar De
- Division of Toxicology
- School of Pharmacy
- Sungkyunkwan University
- Republic of Korea
| | - Falguni Chandra
- Department of Chemistry
- Indian Institute of Science Education and Research Bhopal
- Bhopal 462 066
- India
| | - Niranjan Dehury
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Jatni-752050
- India
| | - Sadhika Khullar
- Department of Chemistry
- Dr. B. R. Ambedkar National Institute of Technology (NIT) Jalandhar
- Jalandhar – 144011
- India
| | - Hyung Sik Kim
- Division of Toxicology
- School of Pharmacy
- Sungkyunkwan University
- Republic of Korea
| | - Srikanta Patra
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Jatni-752050
- India
| |
Collapse
|
13
|
Oh Y, Han SH, Mishra NK, De U, Lee J, Kim HS, Jung YH, Kim IS. Front Cover: Synthesis and Anticancer Evaluation of 2,3-Disubstituted Indoles Derived from Azobenzenes and Internal Olefins (Eur. J. Org. Chem. 42/2017). European J Org Chem 2017. [DOI: 10.1002/ejoc.201701429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Yongguk Oh
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Sang Hoon Han
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | | | - Umasankar De
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Junho Lee
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Hyung Sik Kim
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Young Hoon Jung
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - In Su Kim
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| |
Collapse
|
14
|
Oh Y, Han SH, Mishra NK, De U, Lee J, Kim HS, Jung YH, Kim IS. Synthesis and Anticancer Evaluation of 2,3-Disubstituted Indoles Derived from Azobenzenes and Internal Olefins. European J Org Chem 2017. [DOI: 10.1002/ejoc.201701001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Yongguk Oh
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Sang Hoon Han
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | | | - Umasankar De
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Junho Lee
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Hyung Sik Kim
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - Young Hoon Jung
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| | - In Su Kim
- School of Pharmacy; Sungkyunkwan University; 16419 Suwon Republic of Korea
| |
Collapse
|
15
|
Jeong T, Lee SH, Mishra NK, De U, Park J, Dey P, Kwak JH, Jung YH, Kim HS, Kim IS. Synthesis and Cytotoxic Evaluation of N
-Aroylureas through Rhodium(III)-Catalyzed C−H Functionalization of Indolines with Isocyanates. Adv Synth Catal 2017. [DOI: 10.1002/adsc.201700311] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Taejoo Jeong
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Suk Hun Lee
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Neeraj Kumar Mishra
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Umasankar De
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Jihye Park
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Prasanta Dey
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Jong Hwan Kwak
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Young Hoon Jung
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - Hyung Sik Kim
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| | - In Su Kim
- School of Pharmacy; Sungkyunkwan University; Suwon 16419 Republic of Korea, Fax: (+82)-31-292-8800
| |
Collapse
|
16
|
Sharma S, Oh Y, Mishra NK, De U, Jo H, Sachan R, Kim HS, Jung YH, Kim IS. Rhodium-Catalyzed [3 + 2] Annulation of Cyclic N-Acyl Ketimines with Activated Olefins: Anticancer Activity of Spiroisoindolinones. J Org Chem 2016; 82:3359-3367. [PMID: 28385021 DOI: 10.1021/acs.joc.6b02708] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The rhodium(III)-catalyzed redox-neutral coupling reaction of N-acyl ketimines generated in situ from 3-hydroxyisoindolinones with various activated olefins is described. This approach leads to the synthesis of bioactive spiroisoindolinone derivatives in moderate to high yields. In the case of internal olefins such as maleimides, maleates, fumarates, and cinnamates, spiroindanes were obtained by the [3 + 2] annulations reaction. In sharp contrast, acrylates and quinones displayed the β-H elimination followed by Prins-type cyclization furnishing spiroindenes. The synthetic compounds were evaluated for in vitro anticancer activity against androgen-sensitive human prostate adenocarcinoma cells (LNCaP), human prostate adenocarcinoma cells (DU145), human endometrial adenocarcinoma cells (Ishikawa), human breast cancer cell (MCF-7), and triple negative human breast cancer cells (MDA-MB-231). Notably, quinone-containing spiroindenes displayed potent anticancer activity about 2- to 3-fold stronger than that of anticancer agent doxorubicin.
Collapse
Affiliation(s)
- Satyasheel Sharma
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Yongguk Oh
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Neeraj Kumar Mishra
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Umasankar De
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Hyeim Jo
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Richa Sachan
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Young Hoon Jung
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - In Su Kim
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| |
Collapse
|
17
|
Park EY, Woo Y, Kim SJ, Kim DH, Lee EK, De U, Kim KS, Lee J, Jung JH, Ha KT, Choi WS, Kim IS, Lee BM, Yoon S, Moon HR, Kim HS. Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding. Int J Biol Sci 2016; 12:1555-1567. [PMID: 27994519 PMCID: PMC5166496 DOI: 10.7150/ijbs.13833] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 09/30/2016] [Indexed: 12/28/2022] Open
Abstract
The sirtuins (SIRTs), a family of NAD+-dependent class III histone deacetylase, are involved in various biological processes including cell survival, division, senescence, and metabolism via activation of the stress-response pathway. Recently, inhibition of SIRTs has been considered a promising anticancer strategy, but their precise mechanisms of action are not well understood. In particular, the relevance of p53 to SIRT-induced effects has not been fully elucidated. We investigated the anticancer effects of a novel SIRT inhibitor, MHY2256, and its efficacy was compared to that of salermide in MCF-7 (wild-type p53) and SKOV-3 (null-type p53) cells. Cell viability, SIRT1 enzyme activity, cell cycle regulation, apoptosis, and autophagic cell death were measured. We compared sensitivity to cytotoxicity in MCF-7 and SKOV-3 cells. MHY2256 significantly decreased the viability of MCF-7 (IC50, 4.8 μM) and SKOV-3 (IC50, 5.6 μM) cells after a 48 h treatment period. MHY2256 showed potent inhibition (IC50, 0.27 mM) against SIRT1 enzyme activity compared with nicotinamide (IC50, >1 mM). Moreover, expression of SIRT (1, 2, or 3) protein levels was significantly reduced by MHY2256 treatment in both MCF-7 and SKOV-3 cells. Flow cytometry analysis revealed that MHY2256 significantly induced cell cycle arrest in the G1 phase, leading to an effective increase in apoptotic cell death in MCF-7 and SKOV-3 cells. A significant increase in acetylated p53, a target protein of SIRT, was observed in MCF-7 cells after MHY2256 treatment. MHY2256 up-regulated LC3-II and induced autophagic cell death in MCF-7 cells. Furthermore, MHY2256 markedly inhibited tumor growth in a tumor xenograft model of MCF-7 cells. These results suggest that a new SIRT inhibitor, MHY2256, has anticancer activity through p53 acetylation in MCF-7 human breast cancer cells.
Collapse
Affiliation(s)
- Eun Young Park
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Youngwoo Woo
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Seong Jin Kim
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Do Hyun Kim
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Eui Kyung Lee
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Umasankar De
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 440-746, Republic of Korea
| | - Kyeong Seok Kim
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 440-746, Republic of Korea
| | - Jaewon Lee
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Jee H Jung
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Ki-Tae Ha
- Department of Korean Medical Science, School of Korean Medicine and Korean Medicine Research Center for Healthy Aging, Pusan National University, Yangsan, Gyeongsangnam-do, Republic of Korea
| | - Wahn Soo Choi
- Department of Immunology, School of Medicine, Konkuk University, Chungju 380-701, Republic of Korea
| | - In Su Kim
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 440-746, Republic of Korea
| | - Byung Mu Lee
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 440-746, Republic of Korea
| | - Sungpil Yoon
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 440-746, Republic of Korea
| | - Hyung Ryong Moon
- College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan, 609-735, Republic of Korea
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University, 2066, Seobu-ro, Jangan-gu, Suwon 440-746, Republic of Korea
| |
Collapse
|
18
|
Han SH, Kim S, De U, Mishra NK, Park J, Sharma S, Kwak JH, Han S, Kim HS, Kim IS. Synthesis of Succinimide-Containing Chromones, Naphthoquinones, and Xanthones under Rh(III) Catalysis: Evaluation of Anticancer Activity. J Org Chem 2016; 81:12416-12425. [PMID: 27978756 DOI: 10.1021/acs.joc.6b02577] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The weakly coordinating ketone group directed C-H functionalizations of chromones, 1,4-naphthoquinones, and xanthones with various maleimides under rhodium(III) catalysis are described. These protocols efficiently provide a range of succinimide-containing chromones, naphthoquinones, and xanthones with excellent site selectivity and functional group compatibility. All synthetic compounds were screened for in vitro anticancer activity against human breast adenocarcinoma cell lines (MCF-7). In particular, compounds 7aa and 7ca with a naphthoquinone scaffold were found to be highly cytotoxic, with an activity competitive with anticancer agent doxorubicin.
Collapse
Affiliation(s)
- Sang Hoon Han
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Saegun Kim
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Umasankar De
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Neeraj Kumar Mishra
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Jihye Park
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Satyasheel Sharma
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Jong Hwan Kwak
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Sangil Han
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| | - In Su Kim
- School of Pharmacy, Sungkyunkwan University , Suwon 16419, Republic of Korea
| |
Collapse
|
19
|
Jeon M, Mishra NK, De U, Sharma S, Oh Y, Choi M, Jo H, Sachan R, Kim HS, Kim IS. Rh(III)-Catalyzed C–H Functionalization of Indolines with Readily Accessible Amidating Reagent: Synthesis and Anticancer Evaluation. J Org Chem 2016; 81:9878-9885. [DOI: 10.1021/acs.joc.6b02020] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Affiliation(s)
- Mijin Jeon
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | | | - Umasankar De
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Satyasheel Sharma
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Yongguk Oh
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Miji Choi
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Hyeim Jo
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Richa Sachan
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - In Su Kim
- School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea
| |
Collapse
|
20
|
De U, Kundu A, Kim E, Kwack J, Kim H. Abstract 2984: Plumbagin induces p53-dependent apoptosis via generation of reactive oxygen species in human cancer cells. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2984] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Plumbagin [5-hydroxy-2-methyl-1,4-naphthaquinone], a major constituent derived from Drosera and Plumbago, displays antitumor activity both in vitro and animal models, but the molecular mechanisms of p53-mediated antitumor effects have not been clearly explored. The aim of this study is to determine the anticancer effects of plumbagin on MCF-7 (wild type p53) or Ishikawa (p53-mutant type) cells. We compared the cytotoxicity, cell cycle regulation, apoptotic cell death, and generation of intracellular reactive oxygen species (ROS) in these cancer cells. Plumbagin inhibits the growth of Ishikawa (endometrial cancer cells) and SKOV-3 cells, particularly MCF-7 cells. Plumbagin significantly increased the expression of p53 and reduced Murine Double Minute 2 (MDM2) in the MCF-7 cells. Plumbagin up-regulated the expression of p21(CIP1/WAF1) causing cell cycle arrest in the G2/M-phase by down-regulating cyclin B1 and Cdc2 in MCF-7 as well as Ishikawa cells. Plumbagin altered the ratio of Bax/Bcl-2 and cytochrome c released resulting apoptotic cell death in MCF-7 cells. Furthermore, plumbagin dramatically increased the intracellular ROS level, and pretreatment with the ROS scavenger, N-acetyl cysteine (NAC), protected against growth inhibition by plumbagin, suggesting that ROS play a pivotal role in the antitumor activity in MCF-7 cells. In mice bearing the MCF-7 cell xenografts, plumbagin significantly reduced the tumor growth and weight, without apparent side effects. In conclusion, plumbagin exerted anticancer activity in MCF-7 by generation of intracellular ROS that causes induction of apoptosis via Bcl-2/Bax pathways as well as cell cycle arrest.
KEYWORDS: Plumbagin; breast cancer; apoptosis; p53, reactive oxygen species
Citation Format: Umasankar De, Amit Kundu, Eunbin Kim, Jonghwan Kwack, Hyungsik Kim. Plumbagin induces p53-dependent apoptosis via generation of reactive oxygen species in human cancer cells. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2984.
Collapse
Affiliation(s)
- Umasankar De
- Sungkyunkwan University (SKKU), Suwon, Republic of Korea
| | - Amit Kundu
- Sungkyunkwan University (SKKU), Suwon, Republic of Korea
| | - Eunbin Kim
- Sungkyunkwan University (SKKU), Suwon, Republic of Korea
| | - Jonghwan Kwack
- Sungkyunkwan University (SKKU), Suwon, Republic of Korea
| | - Hyungsik Kim
- Sungkyunkwan University (SKKU), Suwon, Republic of Korea
| |
Collapse
|
21
|
Tripathy SK, De U, Dehury N, Laha P, Panda MK, Kim HS, Patra S. Cyclometallated iridium complexes inducing paraptotic cell death like natural products: synthesis, structure and mechanistic aspects. Dalton Trans 2016; 45:15122-15136. [DOI: 10.1039/c6dt00929h] [Citation(s) in RCA: 42] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Mononuclear cyclometallated iridium complexes of polypyridyl-phenazine based ligands have been synthesized and characterized which display excellent anticancer activity through paraptosis.
Collapse
Affiliation(s)
- Suman Kumar Tripathy
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007
- India
| | - Umasankar De
- Division of Toxicology
- School of Pharmacy
- Sungkyunkwan University
- Gyeonggi-do
- Republic of Korea
| | - Niranjan Dehury
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007
- India
| | - Paltan Laha
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007
- India
| | - Manas Kumar Panda
- National Institute for Interdisciplinary Science and Technology (NIIST)
- Thiruvananthapuram – 695 019
- India
| | - Hyung Sik Kim
- Division of Toxicology
- School of Pharmacy
- Sungkyunkwan University
- Gyeonggi-do
- Republic of Korea
| | - Srikanta Patra
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007
- India
| |
Collapse
|
22
|
De U, Kundu S, Patra N, Ahn MY, Ahn JH, Son JY, Yoon JH, Moon HR, Lee BM, Kim HS. A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1. Biomol Ther (Seoul) 2015; 23:434-41. [PMID: 26336583 PMCID: PMC4556203 DOI: 10.4062/biomolther.2015.026] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Revised: 05/01/2015] [Accepted: 05/06/2015] [Indexed: 12/14/2022] Open
Abstract
Histone deacetylase (HDAC) inhibitors are considered novel agents for cancer chemotherapy. We previously investigated MHY219, a new HDAC inhibitor, and its potent anticancer activity in human prostate cancer cells. In the present study, we evaluated MHY219 molecular mechanisms involved in the regulation of prostate cancer cell migration. Similar to suberanilohydroxamic acid (SAHA), MHY219 inhibited HDAC1 enzyme activity in a dose-dependent manner. MHY219 cytotoxicity was higher in LNCaP (IC50=0.67 μM) than in DU145 cells (IC50=1.10 μM) and PC3 cells (IC50=5.60 μM) after 48 h of treatment. MHY219 significantly inhibited the HDAC1 protein levels in LNCaP and DU145 cells at high concentrations. However, inhibitory effects of MHY219 on HDAC proteins levels varied based on the cell type. MHY219 significantly inhibited LNCaP and DU145 cells migration by down-regulation of matrix metalloprotease-1 (MMP-1) and MMP-2 and induction of tissue inhibitor of metalloproteinases-1 (TIMP-1). These results suggest that MHY219 may potentially be used as an anticancer agent to block cancer cell migration through the repression of MMP-1 and MMP-2, which is related to the reduction of HDAC1.
Collapse
Affiliation(s)
- Umasankar De
- School of Pharmacy, Sungkyunkwan University, Suwon 440-746
| | - Soma Kundu
- College of Pharmacy, Pusan National University, Busan 609-735
| | - Nabanita Patra
- College of Pharmacy, Pusan National University, Busan 609-735
| | - Mee Young Ahn
- Department of Oral & Maxillofacial Pathology, College of Dentistry, Wonkwang Bone Regeneration Institute, Daejeon Dental Hospital, Wonkwang University, Daejeon 302-120, Republic of Korea
| | - Ji Hae Ahn
- School of Pharmacy, Sungkyunkwan University, Suwon 440-746
| | - Ji Yeon Son
- School of Pharmacy, Sungkyunkwan University, Suwon 440-746
| | - Jung Hyun Yoon
- College of Pharmacy, Pusan National University, Busan 609-735
| | | | - Byung Mu Lee
- School of Pharmacy, Sungkyunkwan University, Suwon 440-746
| | - Hyung Sik Kim
- School of Pharmacy, Sungkyunkwan University, Suwon 440-746
| |
Collapse
|
23
|
Shin Y, Han S, De U, Park J, Sharma S, Mishra NK, Lee EK, Lee Y, Kim HS, Kim IS. Ru(II)-Catalyzed Selective C–H Amination of Xanthones and Chromones with Sulfonyl Azides: Synthesis and Anticancer Evaluation. J Org Chem 2014; 79:9262-71. [DOI: 10.1021/jo501709f] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Youngmi Shin
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Sangil Han
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Umasankar De
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Jihye Park
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Satyasheel Sharma
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Neeraj Kumar Mishra
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Eui-Kyung Lee
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - Youngil Lee
- Department
of Chemistry, University of Ulsan, Ulsan 680-749, Republic of Korea
| | - Hyung Sik Kim
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| | - In Su Kim
- School
of Pharmacy, Sungkyunkwan University, Suwon 440-746, Republic of Korea
| |
Collapse
|
24
|
Kim HS, Um YM, Shin MK, Park HJ, Lee JD, Kim JY, Gwak HM, Hyeon JH, Son JY, Kim KS, Sachan R, De U, Kang YJ, Lee BM. Oxidative stress of silver nanoparticles and genetoxic effect of co-treatment with zinc sulfate or manganese (II) chloride in human carcinoma cell lines. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Lee BM, Kim JY, Chung BY, Shin MK, Park HJ, Lee JD, Gwak HM, Hyeon JH, Um YM, Son JY, Kim KS, Sachan R, De U, Kang YJ. Human risk assessment of endocrine disrupting chemicals associated ingredients of household plastic containers. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
26
|
Lee BM, Lee JD, Kim KB, Park HJ, Kim JY, Gwak HM, Hyeon JH, Um YM, Son JY, Kim KS, Sachan R, De U, Kang YJ, Shin MK. Adriamycin efficacy as anti-cancer agents from 1H NMR-based metabolomics studies. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
27
|
Lee BM, Lee JD, Lim DS, Shin MK, Park HJ, Kim JY, Gwak HM, Hyeon JH, Um YM, Son JY, Kim KS, Sachan R, De U, Kang YJ. Comparison of efficacy and bioequivalence between bepotastine/nicotinate and bepotastine/salicylate of antihistamine drugs. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Park HJ, Shin MK, Lee JD, Kim JY, Gwak HM, Hyeon JH, Um YM, Son JY, Kim KS, Sachan R, De U, Kang YJ, Lee BM. Chemopreventive effects of methionine on benzo[a]pyrene (B[a]P)-DNA adducts formation in human hepatocellular carcinoma cells. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
29
|
Park HJ, Kim MJ, Shin MK, Lee JD, Kim JY, Gwak HM, Hyeon JH, Um YM, Son JY, Kim KS, Sachan R, De U, Kang YJ, Lee BM. Human health risk assessment of phenoxyethanol in cosmetics. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
30
|
Kim HS, Hyeon JH, Shin MK, Park HJ, Lee JD, Kim JY, Gwak HM, Um YM, Son JY, Kim KS, Sachan R, De U, Kang YJ, Lee BM. Human risk assessment and GC/MS analysis of phthalates in excipients for pharmaceuticals. Toxicol Lett 2014. [DOI: 10.1016/j.toxlet.2014.06.380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
31
|
Tripathy SK, De U, Dehury N, Pal S, Kim HS, Patra S. Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity. Dalton Trans 2014; 43:14546-9. [DOI: 10.1039/c4dt01033g] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Heterodinuclear Ir–Ru (2) with polypyridyl based phpy ligand shows autophagy induced cell death, whereas homodinuclear Ru–Ru (1) is inactive.
Collapse
Affiliation(s)
- Suman Kumar Tripathy
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007, India
| | - Umasankar De
- Division of Toxicology
- School of Pharmacy
- Sungkyunkwan University
- Suwon, Gyeonggi-do, Republic of Korea
| | - Niranjan Dehury
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007, India
| | - Satyanarayan Pal
- Department of Chemistry, Ravenshaw University
- Cuttack 753 003, Orissa, India
| | - Hyung Sik Kim
- Division of Toxicology
- School of Pharmacy
- Sungkyunkwan University
- Suwon, Gyeonggi-do, Republic of Korea
| | - Srikanta Patra
- School of Basic Sciences
- Indian Institute of Technology Bhubaneswar
- Bhubaneswar-751007, India
| |
Collapse
|
32
|
De U, Chun P, Choi WS, Lee BM, Kim ND, Moon HR, Jung JH, Kim HS. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression. Int J Oncol 2013; 44:167-76. [PMID: 24190517 DOI: 10.3892/ijo.2013.2160] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2013] [Accepted: 10/14/2013] [Indexed: 11/06/2022] Open
Abstract
New potential chemotherapeutic strategies are required to overcome multidrug resistance (MDR) in cancer. This study investigated the anticancer effect of a novel anthracene derivative MHY412 on doxorubicin-resistant human breast cancer (MCF-7/Adr) cells. We measured cell viability and the expression of apoptosis-related genes; in addition, the antitumor activity of MHY412 was confirmed using an in vivo tumor xenograft model. MHY412 significantly inhibited the proliferation of MCF-7/Adr and MCF-7 cells in a concentration-dependent manner. Notably, the half-maximal inhibitory concentration (IC50) values of MHY412 in MCF-7/Adr (0.15 µM) and MCF-7 (0.26 µM) cells were lower than those of doxorubicin (MCF-7/Adr, 13.6 µM and MCF-7, 1.26 µM) after treatment for 48 h. MHY412 at low concentrations induced S phase arrest, but at high concentrations, the number of MCF-7/Adr cells in the sub-G1 phase significantly increased. MHY412-induced sub-G1 phase arrest was associated with inhibition of cyclin, cyclin-dependent kinase 2 (CDK2) and p21 expression in MCF-7/Adr cells. MHY412 markedly reduced P-glycoprotein (P-gp) expression and increased apoptotic cell death in MCF-7/Adr cells. Cleavage of poly-ADP ribose polymerase, reduced Bcl-2 expression, and increased in cytochrome c release in MCF-7/Adr cells confirmed the above results. In addition, MHY412 markedly inhibited tumor growth in a tumor xenograft model of MCF-7/Adr cells. Our data suggest that MHY412 exerts antitumor effects by selectively modulating the genes related to cell cycle arrest and apoptosis. In particular, MHY412 is a new candidate agent for the treatment of Bcl-2 overexpressed doxorubicin-resistant human breast cancer.
Collapse
Affiliation(s)
- Umasankar De
- College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Patra N, De U, Kim TH, Lee YJ, Ahn MY, Kim ND, Yoon JH, Choi WS, Moon HR, Lee BM, Kim HS. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells. Biomed Pharmacother 2013; 67:407-15. [PMID: 23583193 DOI: 10.1016/j.biopha.2013.01.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2013] [Accepted: 01/24/2013] [Indexed: 11/28/2022] Open
Abstract
Histone deacetylase (HDAC) inhibitors are a new class of anticancer agents that act by inhibiting cancer cell proliferation and inducing apoptosis in various cancer cell lines. To investigate the anticancer effect of a novel histone deacetylase (HDAC) inhibitor MHY219, its efficacy was compared to that of suberoylanilide hydroxamic acid (SAHA) in human prostate cancer cells. The anticancer effects of MHY219 on cell viability, HDAC enzyme activity, cell cycle regulation, apoptosis and other biological assays were performed. MHY219 was shown to enhance the cytotoxicity on DU145 cells (IC₅₀, 0.36 μM) when compared with LNCaP (IC₅₀, 0.97 μM) and PC3 cells (IC₅₀, 5.12 μM). MHY219 showed a potent inhibition of total HDAC activity when compared with SAHA. MHY219 increased histone H3 hyperacetylation and reduced the expression of class I HDACs (1, 2 and 3) in prostate cancer cells. MHY219 effectively increased the sub-G1 fraction of cells through p21 and p27 dependent pathways in DU145 cells. MHY219 significantly induced a G2/M phase arrest in DU145 and PC3 cells and arrested the cell cycle at G0/G1 phase in LNCaP cells. Furthermore, MHY219 effectively increased apoptosis in DU145 and LNCaP cells, but not PC3 cells, according to Annexin V/PI staining and Western blot analysis. These results indicate that MHY219 is a potent HDAC inhibitor that targets regulating multiple aspects of cancer cell death and might have preclinical value in human prostate cancer chemotherapy, warranting further investigation.
Collapse
Affiliation(s)
- Nabanita Patra
- Laboratory of Molecular Toxicology, College of Pharmacy, Pusan National University, San 30, Jangjeon-dong, Geumjeung-gu, Busan 609-735, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Patra N, De U, Kang JA, Kim JM, Ahn MY, Lee J, Jung JH, Chung HY, Moon HR, Kim HS. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Eur J Pharmacol 2011; 658:98-107. [DOI: 10.1016/j.ejphar.2011.02.015] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2010] [Revised: 02/07/2011] [Accepted: 02/17/2011] [Indexed: 10/18/2022]
|
35
|
De U, Das S, Sarkar S. Type VI choledochal cyst revisited. Singapore Med J 2011; 52:e91-e93. [PMID: 21633759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Choledochal cysts are rare cystic dilatations of the bile ducts, which are commonly found in children. Choledochal cysts in adults are uncommon, and cystic dilatation of the cystic duct (type VI choledochal cyst) is a unique occurrence. To date, specific pathogenic and diagnostic criteria for describing type VI cysts have been lacking. This report attempts to lay down the specific diagnostic and management criteria of this uncommon entity, with reviews of all available cases reported in the literature.
Collapse
Affiliation(s)
- U De
- Department of Surgery, Calcutta Medical College, 88 College Street, Kolkata 700073, West Bengal, India.
| | | | | |
Collapse
|
36
|
Chakraborty U, Chakraborty B, Allay S, De U, Chakraborty A. DUAL APPLICATION OF BACILLUS PUMILUS AND GLOMUS MOSSEAE FOR IMPROVEMENT OF HEALTH STATUS OF MANDARIN PLANTS. ACTA ACUST UNITED AC 2011. [DOI: 10.17660/actahortic.2011.892.25] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
37
|
Abstract
AIMS The current status of sigmoid volvulus (SV) was reviewed to assess trends in management and to assess the literature. METHOD The literature on SV was retrieved using PubMed, Embase, Scopus, Pakmedinet, African Journals online (AJOL), Indmed and Google scholar. These databases were searched for text words including 'sigmoid', 'colon' and 'volvulus'. Relevant nonindexed surgical journals published from endemic countries were also manually searched. We focused on original articles published within the last 10 years; but classical references prior to this period were also included. Seminal papers published in non-English languages were also included. RESULTS Sigmoid volvulus is a leading cause of acute colonic obstruction in South America, Africa, Eastern Europe and Asia. It is rare in developed countries such as USA, UK, Japan and Australia. Characteristic geographic variations in the incidence, clinical features, prognosis and comorbidity of SV justify recognition of endemic and sporadic subtypes. Controversy on aetiologic agents can be minimized by classifying them into 'predisposing' and 'precipitating' factors. Modern imaging systems, although more effective than plain radiographs, are yet to gain popularity. Emergency endoscopic reduction is the treatment of choice in uncomplicated patients. But it is only a temporizing procedure, and it should be followed in most cases by elective definitive surgery. Resection of the redundant sigmoid colon is the gold standard operation. The role of newer nonresective alternatives is yet to be ascertained. Although emergency resection with primary anastomosis (ERPA) has been controversial in the past, it is now increasingly accepted as a safe option with superior results. Management in elderly debilitated patients is extremely difficult. Paediatric SV significantly differs from that in adults. SV is frequently associated with neuropsychiatric diseases, diabetes mellitus and Chagas disease. The overall mortality in recent studies is < 5%. CONCLUSION There are almost no randomised controlled studies. According to the grading system of Oxford Center for Evidence Based Medicine (CEVM), available published evidence is at level 4. The recommendations resulting form this review are of 'C' grade.
Collapse
Affiliation(s)
- V Raveenthiran
- Division of Pediatric Surgery, Annamalai University, Tamilnadu, India.
| | | | | | | |
Collapse
|
38
|
De U, Acharya AN. Recurrent pyogenic cholangitis. J Indian Med Assoc 2001; 99:651-2. [PMID: 12022211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
A 26-year-old male presented with jaundice and recurrent cholangitis. Ultrasonography revealed dilated intra- and extrahepatic biliary tree packed with multiple calculi. Endoscopic retrograde cholangiopancreatography and computerised tomography scan confirmed the findings and a diagnosis of recurrent pyogenic cholangitis was made. Cholecystectomy, choledocholithotomy with removal of stones and Roux-en-Y choledochojejunostomy were performed.
Collapse
Affiliation(s)
- U De
- Department of Surgery, IPGME&R and SSKM Hospital, Calcutta
| | | |
Collapse
|
39
|
De U, Chattopadhya M, Chaudhury S, Sarkar A, Sanyal D, Dey T. Electrical conductivity, thermo-electric power and structure of differently heat-treated CdO. Journal of Physics and Chemistry of Solids 2000; 61:1955-1958. [DOI: 10.1016/s0022-3697(00)00087-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/19/2023]
|
40
|
Pujari PK, Datta T, De U, Ghosh B. Temperature dependence of the positron annihilation parameters in Bi2-xPbxCa2Sr2Cu3Oy and Bi2CaSr2Cu2Oy superconductors. Phys Rev B Condens Matter 1994; 50:3438-3441. [PMID: 9976606 DOI: 10.1103/physrevb.50.3438] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/12/2023]
|
41
|
Rao G, Varadaraju U, Vijayashree R, Padmanabhan K, Balakrishnan R, Mary T, Raju N, Srinivasan R, De U, Janaki J, Radhakrishnan T. High-Tc superconductivity in Ln2−xBaxCu2O5 (1.0⩽x⩽1.6) andLnBa2Cu3O7 (Ln=Dy, Er, Tm, YbandY) compounds. ACTA ACUST UNITED AC 1987. [DOI: 10.1016/0378-4363(87)90198-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|